Menu Search
Equities

Synlogic Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MIN:MUN

Synlogic Inc

Actions
  • Price (EUR)1.20
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.5299
Data delayed at least 15 minutes, as of Oct 31 2024 07:04 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.

  • Revenue in USD (TTM)0.00
  • Net income in USD-3.23m
  • Incorporated2007
  • Employees1.00
  • Location
    Synlogic IncPO Box 30WINCHESTER 01890United StatesUSA
  • Phone+1 (617) 659-2802
  • Fax+1 (302) 636-5454
  • Websitehttps://www.synlogictx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.